Arvinas, Inc. announced that on December 15, 2022, the Board appointed David Loomis, Vice President and Chief Accounting Officer of the Company, age 49, as principal accounting officer of the Company in lieu of Sean Cassidy, Chief Financial Officer and Treasurer of the Company. Mr. Cassidy will continue to serve as the Company’s principal financial officer. Mr. Loomis joins the Company with close to 30 years’ finance experience in a broad array of practice and industry, including Big 4 public accounting, financial services, consulting and manufacturing, with the last 15 years spent in the biotech industry.

Prior to joining Arvinas, Mr. Loomis served as the Vice President and Corporate Controller of Biohaven Pharmaceuticals, Inc. (“Biohaven”) where he was responsible for corporate tax, accounting, reporting, treasury, budgeting and forecasting, among other responsibilities. As one of Biohaven’s earliest employees, Mr. Loomis supported Biohaven’s initial public offering, follow-on offerings, intellectual property transactions, establishment of commercial processes and acquisitions, culminating with the sale of Biohaven’s calcitonin gene-related peptide portfolio to Pfizer Inc. Mr. Loomis received his bachelor’s degree and MBA from Quinnipiac University. On and effective December 15, 2022, upon recommendation from the Nominating and Corporate Governance Committee of the Board, the Board elected Everett Cunningham, age 55, as a director of the Company, effective immediately upon the resignation of Mr. Margus.

Mr. Cunningham was appointed as a Class III director and will serve in accordance with the Amended and Restated Bylaws of the Company until the Company’s 2024 annual meeting of stockholders and thereafter until his successor is duly elected and qualified or until his earlier death, resignation or removal. Mr. Cunningham was also appointed to serve on the Audit Committee of the Board. Following Mr. Cunningham’s appointment, the Audit Committee is now comprised of Linda Bain (Chair), Leslie Norwalk Esq.

and Mr. Cunningham.